SCHEMBL19854538

SCHEMBL19854538

C=CC(=O)NCCOc1ccc(OC(F)(F)c2ccc(CCCCC)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRB P10828 6/20 0.47
ALDH1A1 P00352 2/20 0.46
THRA P10827 5/20 0.46
KMT2A Q03164 7/20 0.43
MEN1 O00255 6/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 1/20 0.43
PPARA Q07869 2/20 0.41
TGM2 P21980 1/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
USP2 O75604 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
SLCO1B3 Q9NPD5 1/20 0.41
SLCO1B1 Q9Y6L6 1/20 0.41
FAAH O00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19854531 0.87 THRB (0.59) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL19856044 0.85 THRB (0.55) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL10362588 0.83 THRB (0.58) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL10363871 0.82 ZDHHC20 (0.58) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL20370412 0.81 THRB (0.46) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL10364148 0.79 TGM2 (0.56) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL19855999 0.78 THRB (0.51) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL19854607 0.78 RARB (0.49) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL19854389 0.78 RARB (0.49) THRBALDH1A1THRAKMT2AMEN1
SCHEMBL19854609 0.78 RARB (0.49) THRBALDH1A1THRAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 US disclosed
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2020-05-26 US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 US disclosed
WO-2018025974-A1 LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE JNC株式会社 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE SP1, MBD2, PAXBP1 THRB 3939/4885ALDH1A1 3826/4885THRA 3929/4885
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device SP1, MBD2, PAXBP1 THRB 3939/4885ALDH1A1 3826/4885THRA 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.